报价延迟最少15分钟:2026/05/10 18:35 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.597 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.56/-10.80
|
|
企业价值
2.66M
|
| 资产负债 |
|
每股账面净值
1.91
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focusedon advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic braininjury (mTBI), or concussion. |
